Published in J Virol on November 01, 1987
Heterogeneity of the human papillomavirus group. J Virol (1989) 4.90
Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A (1988) 3.73
Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J (1988) 3.61
Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol (1990) 3.29
Papillomavirus polypeptides E6 and E7 are zinc-binding proteins. J Virol (1989) 3.01
Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J Virol (1989) 2.76
The region of the HPV E7 oncoprotein homologous to adenovirus E1a and Sv40 large T antigen contains separate domains for Rb binding and casein kinase II phosphorylation. EMBO J (1990) 2.57
The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol (1989) 2.50
Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein. J Virol (1992) 2.24
Inducible and constitutive enhancer domains in the noncoding region of human papillomavirus type 18. J Virol (1988) 2.19
Human papillomavirus type 16 transformation of primary human embryonic fibroblasts requires expression of open reading frames E6 and E7. J Virol (1989) 2.17
Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol (1991) 2.14
In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol (1991) 2.00
Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells. Proc Natl Acad Sci U S A (1989) 1.87
Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. J Virol (1988) 1.85
The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol (1991) 1.74
Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol (1992) 1.71
The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. J Virol (1993) 1.67
Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol (1997) 1.59
Analysis of trans activation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism. J Virol (1991) 1.54
Identification of a novel constitutive enhancer element and an associated binding protein: implications for human papillomavirus type 11 enhancer regulation. J Virol (1989) 1.52
Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J (1993) 1.49
Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J (1992) 1.43
A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J (1989) 1.34
The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J (1996) 1.33
Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol (1993) 1.32
Presence of catenated human papillomavirus type 16 episomes in a cervical carcinoma cell line. J Virol (1989) 1.30
A member of the activator protein 1 family found in keratinocytes but not in fibroblasts required for transcription from a human papillomavirus type 18 promoter. J Virol (1990) 1.28
Transcriptional activation by the papillomavirus E6 zinc finger oncoprotein. EMBO J (1990) 1.27
Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology (2012) 1.23
Papillomavirus E6 oncoproteins. Virology (2013) 1.21
Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol (1996) 1.21
Cellular binding partners of the human papillomavirus E6 protein. Arch Virol (2008) 1.21
Papillomavirus E7 protein binding to the retinoblastoma protein is not required for viral induction of warts. J Virol (1993) 1.17
Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology, and epidemiology. J Clin Pathol (1994) 1.15
Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol (1994) 1.14
Chemical synthesis of human papillomavirus type 16 E7 oncoprotein: autonomous protein domains for induction of cellular DNA synthesis and for trans activation. J Virol (1990) 1.08
Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral transactivators and a phorbol ester. J Virol (1989) 1.04
Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol (1988) 1.03
Role of papillomaviruses. J Clin Pathol (1990) 1.01
Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J Virol (1990) 1.01
Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J Virol (2001) 1.01
Selective suppression of human papillomavirus transcription in non-tumorigenic cells by 5-azacytidine. EMBO J (1988) 0.99
Buffered formalin is the superior fixative for the detection of HPV DNA by in situ hybridization analysis. Am J Pathol (1989) 0.97
The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain. J Virol (2008) 0.94
Single amino acid substitutions in "low-risk" human papillomavirus (HPV) type 6 E7 protein enhance features characteristic of the "high-risk" HPV E7 oncoproteins. Proc Natl Acad Sci U S A (1992) 0.91
A viral-cellular junction fragment from a human papillomavirus type 16-positive tumor is competent in transformation of NIH 3T3 cells. J Virol (1988) 0.88
Role of the vaginal microbiological ecosystem and cytokine profile in the promotion of cervical dysplasia: a case-control study. Infect Dis Obstet Gynecol (2002) 0.88
The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol (2009) 0.87
Induction of anchorage-independent growth of human embryonic fibroblasts with a deletion in the short arm of chromosome 11 by human papillomavirus type 16 DNA. J Virol (1988) 0.84
Human papillomavirus type 18 and intraepithelial lesions of the cervix. Am J Pathol (1994) 0.82
Rat primary embryo fibroblast cells suppress transformation by the E6 and E7 genes of human papillomavirus type 16 in somatic hybrid cells. J Virol (1991) 0.82
Human papillomavirus type 6b DNA required for initiation but not maintenance of transformation of C127 mouse cells. J Virol (1990) 0.79
Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. Bioinformation (2012) 0.77
In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response. Sci Rep (2015) 0.77
Testing for human papillomavirus: basic pathobiology of infection, methodologies, and implications for clinical use. Yale J Biol Med (1992) 0.76
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol (1982) 116.75
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A (1983) 14.73
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature (1985) 11.11
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J (1984) 10.28
Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein. Proc Natl Acad Sci U S A (1986) 7.78
Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J (1986) 7.60
Transactivation of a bovine papilloma virus transcriptional regulatory element by the E2 gene product. Cell (1985) 7.56
A quantitative in vitro focus assay for bovine papilloma virus. Virology (1980) 7.14
Bovine papillomavirus contains multiple transforming genes. Proc Natl Acad Sci U S A (1985) 6.73
In vitro tumorigenic transformation by a defined sub-genomic fragment of bovine papilloma virus DNA. Nature (1980) 6.67
Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol (1987) 6.65
Identification of a second transforming region in bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1984) 5.88
A transcriptional repressor encoded by BPV-1 shares a common carboxy-terminal domain with the E2 transactivator. Cell (1987) 5.75
Nucleotide sequence and comparative analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J Mol Biol (1987) 5.13
Localization and analysis of bovine papillomavirus type 1 transforming functions. J Virol (1984) 4.77
E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol (1986) 4.04
Differential promoter utilization by the bovine papillomavirus in transformed cells and productively infected wart tissues. EMBO J (1987) 3.77
Dissociation of transforming and trans-activation functions for bovine papillomavirus type 1. Nature (1986) 3.63
Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science (1985) 3.21
The transforming function of bovine papillomavirus DNA. Proc Natl Acad Sci U S A (1983) 3.19
Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells. J Virol (1986) 3.03
The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J Virol (1987) 2.90
Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J (1987) 2.56
Human papillomaviruses and cancer. Biochim Biophys Acta (1986) 2.35
Characterization of a cell type-specific enhancer found in the human papilloma virus type 18 genome. EMBO J (1987) 1.67
Human papillomavirus in clinically and histologically normal tissue of patients with genital cancer. N Engl J Med (1986) 1.65
Genital papillomavirus infections. Prog Med Virol (1985) 1.58
Host-specific activation of transcription by tandem repeats from simian virus 40 and Moloney murine sarcoma virus. Proc Natl Acad Sci U S A (1982) 12.30
Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus. J Virol (1984) 7.80
Osmotic control of kdp operon expression in Escherichia coli. Proc Natl Acad Sci U S A (1981) 5.27
Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science (1992) 4.49
Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrob Agents Chemother (1983) 4.25
An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. J Histochem Cytochem (1985) 4.13
Crystal structure at 1.7 A of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target. Nature (1992) 4.12
Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proc Natl Acad Sci U S A (1988) 3.73
Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrob Agents Chemother (1983) 3.46
Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J Virol (1992) 2.99
Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation. J Virol (1991) 2.79
Identification of human papillomavirus type 18 transforming genes in immortalized and primary cells. J Virol (1989) 2.76
The 68-kilodalton E1 protein of bovine papillomavirus is a DNA binding phosphoprotein which associates with the E2 transcriptional activator in vitro. J Virol (1991) 2.65
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (1993) 2.61
In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression. Proc Natl Acad Sci U S A (1996) 2.54
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol (2000) 2.44
Multiple enhancer domains in the 3' terminus of the Prague strain of Rous sarcoma virus. Nucleic Acids Res (1984) 2.28
Inducible and constitutive enhancer domains in the noncoding region of human papillomavirus type 18. J Virol (1988) 2.19
Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes. Proc Natl Acad Sci U S A (1999) 2.00
Identification of the structural proteins of an ATP-driven potassium transport system in Escherichia coli. Proc Natl Acad Sci U S A (1978) 1.98
Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther (1981) 1.88
Human papillomavirus life cycle: active and latent phases. Semin Cancer Biol (1999) 1.88
Randomised controlled trial comparing an acute paediatric hospital at home scheme with conventional hospital care. Arch Dis Child (2002) 1.72
Disposition of radiolabeled imipenem and cilastatin in normal human volunteers. Antimicrob Agents Chemother (1984) 1.63
Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol (1998) 1.63
Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proc Natl Acad Sci U S A (1994) 1.62
Locomotor and sensorimotor performance deficit in rats following exposure to pyridostigmine bromide, DEET, and permethrin, alone and in combination. Toxicol Sci (2001) 1.62
The role of the E1 and E2 proteins in the replication of human papillomavirus type 31b. Virology (1994) 1.61
In vitro systems for the study and propagation of human papillomaviruses. Curr Top Microbiol Immunol (1994) 1.61
c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Differ (1993) 1.60
Induction of human papillomavirus type 18 late gene expression and genomic amplification in organotypic cultures from transfected DNA templates. J Virol (1997) 1.59
Human papillomavirus type 31b late gene expression is regulated through protein kinase C-mediated changes in RNA processing. J Virol (1995) 1.57
Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol (1994) 1.54
Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol (2001) 1.54
Amino acids necessary for DNA contact and dimerization imply novel motifs in the papillomavirus E2 trans-activator. Genes Dev (1992) 1.49
Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma. Am J Hum Genet (1998) 1.44
Bioavailability and metabolism of talampicillin. Chemotherapy (1978) 1.42
The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J Virol (2000) 1.40
Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J Virol (1998) 1.40
Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31. J Virol (1998) 1.37
A keratinocyte-specific transcription factor, KRF-1, interacts with AP-1 to activate expression of human papillomavirus type 18 in squamous epithelial cells. Proc Natl Acad Sci U S A (1991) 1.34
In vitro differentiation of epithelial cells from cervical neoplasias resembles in vivo lesions. Oncogene (1990) 1.32
Cooperative binding of the E2 protein of bovine papillomavirus to adjacent E2-responsive sequences. J Virol (1991) 1.32
Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother (1983) 1.32
Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding. J Virol (1993) 1.32
Differentiation-dependent expression of E1--E4 proteins in cell lines maintaining episomes of human papillomavirus type 31b. Virology (1995) 1.31
Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology (1998) 1.30
DNA replication of human papillomavirus type 31 is modulated by elements of the upstream regulatory region that lie 5' of the minimal origin. J Virol (1999) 1.29
Long interspersed repeated DNA (LINE) causes polymorphism at the rat insulin 1 locus. Mol Cell Biol (1985) 1.29
Intracellular localization and DNA-binding properties of human papillomavirus type 18 E6 protein expressed with a baculovirus vector. J Virol (1989) 1.28
Bioavailability of talampicillin. Br Med J (1977) 1.28
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. Br J Clin Pharmacol (1984) 1.27
Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology (1996) 1.24
Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene (2006) 1.24
The clinical pharmacology of enalapril. J Hypertens Suppl (1983) 1.23
Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J (1997) 1.20
Effects of infusions of magnesium and of calcium in parathyroid insufficiency. Clin Sci (1966) 1.20
E6 protein of human papillomavirus type 18 binds zinc. Oncogene (1989) 1.17
Differentiation-induced changes in promoter usage for transcripts encoding the human papillomavirus type 31 replication protein E1. Virology (1999) 1.14
Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. J Virol (1997) 1.13
Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression. J Virol (2001) 1.13
Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma. Invest Ophthalmol Vis Sci (1998) 1.12
Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. J Gen Virol (1997) 1.10
Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J Virol (2001) 1.08
Regulation of human papillomavirus type 31 polyadenylation during the differentiation-dependent life cycle. J Virol (1999) 1.06
Differential effects of the splice acceptor at nucleotide 3295 of human papillomavirus type 31 on stable and transient viral replication. J Virol (1997) 1.06
Effect of calcium on mental symptoms in partial parathyroid insufficiency. Lancet (1967) 1.05
The 5' region of the human papillomavirus type 31 upstream regulatory region acts as an enhancer which augments viral early expression through the action of YY1. Virology (1997) 1.05
Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral transactivators and a phorbol ester. J Virol (1989) 1.04
Effects of daily dermal application of DEET and epermethrin, alone and in combination, on sensorimotor performance, blood-brain barrier, and blood-testis barrier in rats. J Toxicol Environ Health A (2001) 1.02
The cold-sensitive period for frizzled in the development of wing hair polarity ends prior to the start of hair morphogenesis. Mech Dev (1994) 1.00
Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis (1982) 1.00
Early polyadenylation signals of human papillomavirus type 31 negatively regulate capsid gene expression. J Virol (2001) 1.00
Hamster ova/human sperm penetration: correlation with count, motility, and morphology for in vitro fertilization. Arch Androl (1984) 0.99
Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines. Gynecol Oncol (1993) 0.96
Transcriptional activity of human papillomavirus type 31b enhancer is regulated through synergistic interaction of AP1 with two novel cellular factors. Virology (1995) 0.92
Urban legend versus rural reality: patients' experience of attendance at accident and emergency departments in west Wales. Emerg Med J (2005) 0.92
Propidium iodide as a nuclear counterstain for immunofluorescence studies on cells in culture. J Histochem Cytochem (1987) 0.91
Cytotoxicity of tocopherols and their quinones in drug-sensitive and multidrug-resistant leukemia cells. Lipids (1998) 0.91
Hydride transfer stereospecificity of rat liver aldehyde dehydrogenases. J Biol Chem (1987) 0.89
Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher's syndrome. Lancet (1987) 0.87
EBNA1 and E2: a new paradigm for origin-binding proteins? Trends Microbiol (1996) 0.87
Acute sarin exposure causes differential regulation of choline acetyltransferase, acetylcholinesterase, and acetylcholine receptors in the central nervous system of the rat. Toxicol Sci (2000) 0.87
E6 and E7 expression from the HPV 18 LCR: development of genital hyperplasia and neoplasia in transgenic mice. Oncogene (1995) 0.86
Antioxidant and cytotoxic tocopheryl quinones in normal and cancer cells. Free Radic Biol Med (1995) 0.86
Rapid method for identification of macrophages in suspension by acid alpha-naphthyl acetate esterase activity. J Histochem Cytochem (1983) 0.85
Interferon-inducible genes are major targets of human papillomavirus type 31: insights from microarray analysis. Dis Markers (2001) 0.83
Pharmacokinetics of parenterally administered amoxycillin. J Infect (1980) 0.82
Human epithelial cells immortalized by SV40 retain differentiation capabilities in an in vitro raft system and maintain viral DNA extrachromosomally. Virology (1991) 0.81
HPV-16 viral transcripts in vulvar neoplasia: preliminary studies. Gynecol Oncol (1991) 0.80
Bone marrow transplantation for acute lymphoblastic leukaemia. Br J Haematol (1982) 0.80
EMEA and the new pharmaceutical procedures for Europe. European Medicines Evaluation Agency. Eur J Clin Pharmacol (1995) 0.79
Sympathetic nervous system and glioma growth. Eur J Cancer Clin Oncol (1986) 0.78
Pharmacokinetics and tolerance after repeated doses of imipenem/cilastatin in patients with severe renal failure. J Antimicrob Chemother (1986) 0.78